Project Grant HT94252510483
Award Date
9/30/25
Completion Date
9/29/29
Dollars Obligated
$2.8M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
San Antonio, TX 78229, USA
Similar Awards
This $1,124,825 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research at the University of Texas Health Science Center at San Antonio (UTHSCSA) to identify novel therapeutic targets for aggressive prostate cancer through induced pluripotent stem cell modeling of BRCA2 mutant prostate tissue. The award, which runs from August 1, 2024 to July 31, 2027, will enable UTHSCSA to conduct innovative scientific...
This federal Project Grant award of $2,028,000.00, awarded on April 1, 2025 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research aimed at identifying epigenetically driven vulnerabilities in metastatic castration-resistant prostate cancer. The award was granted to the Icahn School of Medicine at Mount Sinai, a prominent academic medical center and research institution in New York City. Through this...
The Defense Health Agency awarded a $468,000 Project Grant to the University of California, Los Angeles under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing new therapeutic strategies to target TROP2 in aggressive prostate cancer. The two-year award beginning March 15, 2023 will fund research efforts to investigate medical solutions for prostate cancer on the battlefield and transform health care for service members and the public...
This federal Project Grant award of $1,235,845.00 from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports a research project led by the University of Illinois in Chicago. The project aims to leverage data science methods to deliver individualized treatment effects in metastatic hormone sensitive prostate cancer. The award period runs from August 15, 2025 to August 14, 2028. The Military Medical Research and Development program funds...
The federal Project Grant award of $1,225,783 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the development of a fully automated deep learning-based framework for segmentation and treatment response assessment of lesions on PSMA PET/CT in prostate cancer. This research, conducted by the University of Colorado-Denver, aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative...
The University of Texas Health Science Center at San Antonio (UTHSCSA) received a $1,872,750 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on June 1, 2025, supports UTHSCSA's research on "SELISISTAT AS AN ANTI-PROSTATE CANCER AGENT FOR TREATMENT OF PROSTATE CANCER" with a performance period ending on May 31, 2028. As a state-controlled academic medical center with expertise in serving...
This $785,833 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports advanced research to target immunotherapy-resistant lesions and eradicate oligometastatic prostate cancer. Awarded to the University of Wisconsin System, the research aims to transform healthcare for military service members and the broader public by investigating innovative approaches to disease prevention, diagnosis,...
This $1,211,127 Project Grant awarded by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports a research project by the University of California, San Francisco (UCSF) to investigate the importance of immune responses to prostate tumor antigens primed by a combination of radiation and immunotherapy. The 4-year project aims to advance understanding of how to leverage the body's immune system to improve treatments for prostate cancer. As...
This federal Project Grant award for $465,935.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is funding research conducted by the University of Wisconsin - Madison to combine PSMA and BRD4 disruption approaches to overcome resistance in advanced prostate cancer. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative biomedical solutions to critical...
This Project Grant award for $1,126,685 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports translatome profiling research conducted by the University of British Columbia (UBC) to identify biomarkers and therapeutic targets for prostate cancer. The project aims to leverage UBC's expertise in biomedical research and advanced analytical capabilities to advance the understanding and treatment of prostate cancer, which is an...